Richard Martin

Jan 24, 2025 | ascelibrary.org | Richard Martin |J. Scott

Get full access to this articleView all available purchase options and get full access to this article. Data Availability StatementSome or all data, models, or code that support the findings of this study are available from the corresponding author upon reasonable request.

Aug 15, 2024 | jamanetwork.com | Mark Goldstein |Luca Mascitelli |Centro Medico Esperia |Richard Martin

Prostate-Specific Antigen Screening and 15-Year Prostate Cancer Mortality Richard M. Martin, BM, BS, PhD; Emma L. Turner, PhD; Grace J. Young, MSc; Chris Metcalfe, PhD; Eleanor I. Walsh, MSc; J. Athene Lane, PhD; Jonathan A. C. Sterne, PhD; Sian Noble, PhD; Peter Holding, MSc; Yoav Ben-Shlomo, MBBS, PhD; Naomi J. Williams, PhD; Nora Pashayan, MD, PhD; Mai Ngoc Bui, PhD; Peter C. Albertsen, MD; Tyler M. Seibert, MD, PhD; Anthony L. Zietman, MD; Jon Oxley, MD; Jan Adolfsson, MD; Malcolm D.

Apr 28, 2024 | nature.com | Karl Smith-Byrne |Marios Dimitriou |Mine Koprulu |Maik Pietzner |Claudia Langenberg |Joshua Atkins | +10 more

AbstractCirculating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis protein Mendelian randomisation and colocalization. We conduct additional analyses to identify adverse side-effects of altering risk proteins and map cancer risk proteins to drug targets.